Canaccord Lowers Regeneron Price Target After Disappointing Phase 3 Trial Outcome QYLDs High 12 Yield Could Attract Income Seekers but LongTerm Total Return Raises Questions Novartis Lifts FullYear Sales and Profit Outlook Amid Strong Operational Performance Chinas Humanoid Robot Training Programs Raise Competitive Stakes Kevin Warsh Faces Divided Fed Over Rate Cut Prospects as Inflation and Yields Surge Bernstein Maintains Outperform Rating on UnitedHealth Amid PBM Transparency Developments Graphic Packaging Turnaround May Be in Early Stages Baird Analyst Indicates